Mounjaro® KwikPen® 15 mg (Tirzepatide)

Mounjaro® KwikPen® 15 mg is a prescription injectable medicine containing Tirzepatide 15 mg/0.6 mL. It is a once-weekly subcutaneous injection used along with diet and exercise to improve blood sugar control in appropriate patients with type 2 diabetes mellitus. Each multi-dose KwikPen contains 2.4 mL of solution and delivers four doses of 15 mg.

Category: Diabetes / Antidiabetic Medicine

Description

Mounjaro® KwikPen® 15 mg contains Tirzepatide, a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist. It is designed to help improve glycemic control in patients with type 2 diabetes when used together with an appropriate diet and exercise program.

Tirzepatide works by activating both GIP and GLP-1 receptors. It enhances glucose-dependent insulin secretion, reduces glucagon secretion and can decrease food intake. These actions contribute to lowering blood glucose levels.

The Mounjaro KwikPen is designed for subcutaneous administration once weekly. The 15 mg KwikPen contains 2.4 mL of solution and provides four weekly doses of 15 mg/0.6 mL.

Clean Listing Description

Mounjaro® KwikPen® 15 mg (Tirzepatide) is a prescription injectable medicine manufactured by Eli Lilly and Company. It contains Tirzepatide 15 mg per 0.6 mL dose and is supplied in a multi-dose prefilled pen containing 2.4 mL solution, sufficient for four 15 mg doses. It is administered subcutaneously once weekly under appropriate medical supervision.

Tirzepatide acts on both GIP and GLP-1 receptors and helps regulate glucose-dependent insulin secretion and glucagon levels. It also affects food intake and gastric emptying, contributing to its metabolic effects.

Product Details

• Product Name: Mounjaro® KwikPen®
• Active Ingredient: Tirzepatide
• Strength: 15 mg/0.6 mL
• Total Volume: 2.4 mL
• Total Content: 60 mg Tirzepatide
• Dosage Form: Injectable Solution
• Device: Multi-dose Prefilled KwikPen
• Doses per Pen: 4 doses
• Dose per Administration: 15 mg
• Route: Subcutaneous
• Frequency: Once weekly
• Manufacturer: Eli Lilly and Company
• Category: Antidiabetic / GIP & GLP-1 Receptor Agonist
• Prescription: Required

Uses

Mounjaro is prescribed, along with diet and exercise, to improve glycemic control in:

• Adults with type 2 diabetes mellitus
• Pediatric patients aged 10 years and older with type 2 diabetes mellitus, where indicated by the prescribing information

How It Works

Tirzepatide activates both GIP and GLP-1 receptors. It enhances glucose-dependent insulin secretion and reduces glucagon secretion. It also reduces food intake and produces other metabolic effects that contribute to improved blood glucose control.

Administration

Mounjaro is administered as a subcutaneous injection once weekly. It may be administered at any time of day, with or without meals. Injection sites include the abdomen or thigh; administration in the back of the upper arm should be performed by another person. Injection sites should be rotated with each dose.

The 15 mg KwikPen contains four 15 mg doses, with each dose delivered from 0.6 mL of solution.

Important Safety Information

Mounjaro carries a boxed warning regarding the risk of thyroid C-cell tumors observed in rats. It is not known whether this risk applies to humans. Mounjaro is contraindicated in people with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Common adverse reactions include gastrointestinal symptoms such as nausea, diarrhea, decreased appetite, vomiting, constipation, indigestion and abdominal discomfort. More serious risks can occur, including severe gastrointestinal reactions, pancreatitis, gallbladder problems, hypoglycemia when used with certain other diabetes medicines, and hypersensitivity reactions.

Mounjaro should be used only according to the prescription and instructions provided by a qualified healthcare professional. Patients should inform their doctor about their medical history and all medicines they are taking before starting treatment.

Storage

Mounjaro should be stored in accordance with the official product instructions. The product should not be frozen and should be protected from excessive heat and light. Refrigerated storage is specified for the appropriate Mounjaro presentations.

Disclaimer: This product description is provided for informational and product-listing purposes only. Mounjaro is a prescription medicine and should be used only under the supervision of a qualified healthcare professional. Always follow the current official prescribing information applicable to your country.